Literature DB >> 32584817

The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers.

Denis Malvy1,2, Anne-Marie Taburet3, Xavier de Lamballerie4, France Mentre5, Fabrice Extramiana6.   

Abstract

Entities:  

Year:  2020        PMID： 32584817     DOI： 10.1371/journal.pntd.0008259

Source DB:  PubMed          Journal:  PLoS Negl Trop Dis        ISSN： 1935-2727


× No keyword cloud information.
  5 in total

1.  Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia.

Authors:  Faryal Khamis; Hanan Al Naabi; Adil Al Lawati; Zaiyana Ambusaidi; Mariam Al Sharji; Umkulthum Al Barwani; Nenad Pandak; Zakariya Al Balushi; Maher Al Bahrani; Issa Al Salmi; Ibrahim Al-Zakwani
Journal:  Int J Infect Dis       Date:  2020-11-09       Impact factor: 3.623

2.  Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database.

Authors:  Rimple Jeet Kaur; Jaykaran Charan; Siddhartha Dutta; Paras Sharma; Pankaj Bhardwaj; Praveen Sharma; Halyna Lugova; Ambigga Krishnapillai; Salequl Islam; Mainul Haque; Sanjeev Misra
Journal:  Infect Drug Resist       Date:  2020-12-14       Impact factor: 4.003

Review 3.  Interaction of SARS-CoV-2 with cardiomyocytes: Insight into the underlying molecular mechanisms of cardiac injury and pharmacotherapy.

Authors:  Abdulhamid Abdi; Shahad AlOtaiby; Firas Al Badarin; Ali Khraibi; Hamdan Hamdan; Moni Nader
Journal:  Biomed Pharmacother       Date:  2021-12-09       Impact factor: 7.419

4.  High doses of favipiravir in two men survivors of Ebola virus disease carrying Ebola virus in semen in Guinea.

Authors:  Philippine Eloy; Cédric Laouénan; Abdoul Habib Beavogui; Sakoba Keita; Pauline Manchon; Jean-François Etard; Daouda Sissoko; France Mentré; Denis Malvy
Journal:  IDCases       Date:  2022-01-21

5.  The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.

Authors:  Soheil Hassanipour; Morteza Arab-Zozani; Bahman Amani; Forough Heidarzad; Mohammad Fathalipour; Rudolph Martinez-de-Hoyo
Journal:  Sci Rep       Date:  2021-05-26       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.